Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update

Keros Therapeutics, Inc. (NASDAQ:KROS) was the recipient of a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 2,031,197 shares, a drop of 14.8% from the February 12th total of 2,383,895 shares. Currently, 8.6% of the company’s stock are short sold. Based on an average daily trading volume, of 307,757 shares, the short-interest ratio is currently 6.6 days. Based on an average daily trading volume, of 307,757 shares, the short-interest ratio is currently 6.6 days. Currently, 8.6% of the company’s stock are short sold.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in KROS. Western Standard LLC boosted its stake in Keros Therapeutics by 42.7% in the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after purchasing an additional 654,989 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Keros Therapeutics by 282.5% in the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after buying an additional 436,986 shares during the period. Canada Pension Plan Investment Board acquired a new position in Keros Therapeutics in the 2nd quarter worth approximately $4,251,000. Caption Management LLC raised its position in Keros Therapeutics by 114.1% during the 2nd quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after buying an additional 291,997 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in Keros Therapeutics by 683.7% during the 3rd quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after acquiring an additional 264,445 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Stock Up 0.3%

Shares of Keros Therapeutics stock opened at $11.02 on Monday. The company has a market cap of $217.31 million, a P/E ratio of 6.05 and a beta of 0.87. The firm’s 50 day moving average price is $16.53 and its 200-day moving average price is $16.93. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, March 4th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.37). Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. The firm had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $3.66 million. During the same period in the previous year, the company earned ($1.14) EPS. The company’s revenue was down 87.2% on a year-over-year basis. As a group, equities research analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KROS has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Wall Street Zen cut shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Zacks Research cut Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, TD Cowen raised Keros Therapeutics to a “hold” rating in a research report on Friday, December 19th. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $21.86.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.